Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
NCT ID: NCT02166437
Last Updated: 2016-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2013-11-30
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Teriparatide Therapy for Japanese
NCT01956461
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
NCT02156960
Effects of Denosumab Therapy for Japanese
NCT02491515
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
NCT03702140
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT01750086
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alendronate
Patients treated with alendronate
No interventions assigned to this group
Minodronate
Patients treated with minodronate
No interventions assigned to this group
Denosmab
Patients treated with denosmab
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tomidahama Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Toshihiko Kono
Head of Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rui Niimi, MD, PhD
Role: STUDY_DIRECTOR
Tomidahama Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tomidahama Hospital
Yokkaichi, Mie-ken, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB TH No 6-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.